At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 389 enrolled
Drug / intervention
LCZ696 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension
In Brief
A Phase 2 clinical trial evaluating LCZ696 and Placebo for Hypertension. Completed, enrolled 389 participants across 34 sites in 5 countries.
Detailed Summary
This study is a phase 2 study in patients with essential hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesChina, Japan, South Korea, Taiwan, Thailand
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedSep 2010
Primary CompletionApr 2011
TodayJul 2026
First PostedSep 1, 2010
Enrollment StartAug 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.8 years ago
Interventions
LCZ696drug
LCZ696
Placebodrug
matching placebo to LCZ696